AstraZeneca announced its acquisition of Amolyt Pharma, a company focused on endocrine diseases, for $1.05 billion in cash. This move aims ...

In almost a decade since AstraZeneca fended off a takeover by U.S. rival Pfizer, CEO Pascal Soriot has rebuilt the Anglo-Swedish drugmaker'...

Soriot was tasked with turning around a troubled AstraZeneca - hit by a string of key patent losses and a spate of clinical trial failures ...

Net profit slumped 64 percent to $746 million compared with the first six months of last year, AstraZeneca said in a statement. Operating e...

At an annual meeting of shareholders, 60.19% of votes were cast by shareholders in favour of approving Soriot's pay proposal, which takes h...

Soriot said the company did its best to deliver as much as it could to the EU, and while he was disappointed it could not have delivered mo...

The development of the vaccine with scientists at Oxford University -- and their decision to make it available at cost -- has made the Angl...

Researchers began this work months ago when the variants were first detected, said Mene Pangalos, head of biopharmaceuticals research for A...

AstraZeneca chief executive Pascal Soriot, speaking at a virtual event for the Davos World Economic Forum, also attacked a lack of global p...

The UK government announced on December 23 that the developers of the Oxford AstraZeneca vaccine had submitted their data to the Medicines ...

Chief Executive Officer Pascal Soriot had told reporters on Saturday that the deal, a bet on rare-disease and immunology drugs, was the res...

AstraZeneca Chief Executive Officer Pascal Soriot said the drugmaker had begun submitting data to regulatory authorities around the world t...

“Now that we’ve found what looks like a better efficacy we have to validate this, so we need to do an additional study,” CEO Pascal Soriot ...

The British drugmaker said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side effects.

AstraZeneca said on Saturday that it had signed contracts with France, Germany, Italy and the Netherlands to supply the European Union with...

“We’re manufacturing indeed at risk — and that’s the only way to have the vaccine ready to go if it works,” he added. Oxford University beg...

AstraZeneca's boss said he would engage with Pfizer if the price was right and the risks posed from forcing the British drugmaker's ops int...